Literature DB >> 11765837

Chordomas of the craniocervical junction: follow-up review and prognostic factors.

B Colli1, O Al-Mefty.   

Abstract

OBJECT: Chordomas are rare tumors that arise from the remnants of the notochord. Because of their deep location, local infiltrative nature, and involvement of surrounding bone, treatment of chordomas is a challenge. In this study the authors analyze the data and prognostic factors obtained during the follow-up period (range 1-150 months, median 38 months) in 53 patients with craniocervical junction chordomas and 10 patients with chondrosarcomas.
METHODS: Several surgical approaches were used, and some tumor excisions required staged procedures. Survival was calculated according the Kaplan-Meier method. Statistical analysis was performed using Fisher exact, log rank and Kruskal-Wallis tests. Radical/subtotal resection was achieved in 77.8% of the patients. The mortality rate during the follow-up period was 14.3%. In patients harboring chondrosarcoma better 5-year recurrence-free survival (RFS) rates were demonstrated than in those with chordoma (100% and 50.7%. respectively). Histological patterns (typical or chondroid chordomas) and patient age at onset of symptoms had no effect on the RFS rates. Radical/subtotal resections were associated with better RFS rates than partial resection. Adjuvant proton-beam therapy was shown to increase the RFS rates compared with conventional radiotherapy (90.9% and 19.4%, respectively, at 4 years posttreatment). Karyotypically abnormal tumors were associated with the worst RFS rates compared with karyotypically normal lesions (44.5% and 90.3%, respectively, at 3 years). Cases of cranial nerve palsy followed by those with cerebrospinal fluid leakages were the most frequent postoperative complications. Permanent postoperative neurological deficit was observed in 28.6% of the patients.
CONCLUSIONS: A better prognosis was observed in patients with chondrosarcoma compared with those harboring chordoma. Histological pattern and patient age at symptom onset were not factors that influenced prognosis in cases of chordoma. Extensive resection and possibly adjuvant proton-beam therapy provided better prognoses for these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11765837     DOI: 10.3171/jns.2001.95.6.0933

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  34 in total

Review 1.  Clinical evidence of particle beam therapy (proton).

Authors:  Takashi Ogino
Journal:  Int J Clin Oncol       Date:  2012-03-17       Impact factor: 3.402

2.  Chondrosarcoma of the clivus presenting with intratumoral hemorrhage: case report.

Authors:  Kei Harada; Ichiro Nakahara; Junya Hayashi; Masato Tanaka; Yasuhiko Akiyama; Yasushi Iwamuro; Motoaki Fujimoto
Journal:  J Neurooncol       Date:  2005-12-07       Impact factor: 4.130

Review 3.  Endoscopic endonasal skull base surgery: past, present and future.

Authors:  Paolo Castelnuovo; Iacopo Dallan; Paolo Battaglia; Maurizio Bignami
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-09       Impact factor: 2.503

Review 4.  Promise and pitfalls of heavy-particle therapy.

Authors:  Timur Mitin; Anthony L Zietman
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

5.  Hyperfractionated high-dose proton beam radiotherapy for clival chordomas after surgical removal.

Authors:  Yasutaka Hayashi; Masashi Mizumoto; Hiroyoshi Akutsu; Shingo Takano; Akira Matsumura; Toshiyuki Okumura; Takuya Kawabe; Junko Zenkoh; Hideyuki Sakurai; Koji Tsuboi
Journal:  Br J Radiol       Date:  2016-04-21       Impact factor: 3.039

Review 6.  Chordomas of the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients.

Authors:  Muneyoshi Yasuda; Damien Bresson; Salvatore Chibbaro; Jan F Cornelius; Marc Polivka; Loic Feuvret; Masakazu Takayasu; Bernard George
Journal:  Neurosurg Rev       Date:  2011-08-24       Impact factor: 3.042

7.  Surgical management of petroclival chordomas: report of eight cases.

Authors:  Toshihiro Takami; Kenji Ohata; Takeo Goto; Naohiro Tsuyuguchi; Akimasa Nishio; Mitsuhiro Hara
Journal:  Skull Base       Date:  2006-05

8.  Update on the cytogenetics and molecular genetics of chordoma.

Authors:  Lidia Larizza; Pietro Mortini; Paola Riva
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

Review 9.  A systematic review of proton therapy in the treatment of chondrosarcoma of the skull base.

Authors:  Maurizio Amichetti; Dante Amelio; Marco Cianchetti; Riccardo Maurizi Enrici; Giuseppe Minniti
Journal:  Neurosurg Rev       Date:  2010-04       Impact factor: 3.042

10.  Chordomas and chondrosarcomas of the skull base: comparative analysis of clinical results in 30 patients.

Authors:  Young Hyun Cho; Jeong Hoon Kim; Shin Kwang Khang; Jung-Kyo Lee; Chang Jin Kim
Journal:  Neurosurg Rev       Date:  2007-10-09       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.